Please login to the form below

Not currently logged in
Email:
Password:

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option
STX-Med Cefaly for migraine

The US FDA has approved a drug-free regimen to treat migraines that involves the use of an electronic headband.

Known as Cefaly the battery-powered device is worn across the forehead and behind the ears and applies an electric current to the skin to stimulate the trigeminal nerve, which is associated with migraine headaches.

The approval covers use of Cefaly in patients aged 18 and over and the device should only be used once per day for 20 minutes.

Christy Foreman, part of the FDA's Center for Devices and Radiological Health, said Cefaly offers an alternative to medication in the treatment of migraine, which involves an intense throbbing pain the head and is thought to affect 10 per cent of the world's population.

“This may help patients who cannot tolerate current migraine medications for preventing migraines or treating attacks,” added Foreman.

Manufactured by Belgian medical device company STX-Med, Cefaly has demonstrated its effectiveness in a clinical study involving 67 individuals who experienced more than two migraine headache attacks a month and who had not taken any medicines to prevent migraines for three months prior to using the device.

This study showed that people using Cefaly experience fewer migraines per month and used less medication than those on placebo.

These findings were corroborated by a patient satisfactions study, which showed that just over half of 2,313 users were willing to buy the device for continues use.

The approval provides competition to current drugs available to tackle the symptoms of migraine, including injectable therapies, nasal sprays and oral drugs, although use of the latter two can be limited due to the nausea associated with migraine while the former can be invasive and difficult to administer.

This has meant focus has moved to device-type treatments, including Cefaly and sumatriptan skin patch Zecuity, marketed by pain specialist NuPathe, which is now at the centre of an attempted takeover by Teva.

12th March 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics